The makers of voclosporin, an experimental drug being studied as a possible alternative to cyclosporin for psoriasis, organ transplant, eye disease and other uses, faced a setback last week as the U.S. Food and Drug Administration (FDA) asked for an additional Phase Three study of the drug’s use in uveitis, an eye disorder. The news sent shares of voclosporin’s inventor, Isotechnika, down sharply, as reported by Reuters:
The U.S. Food and Drug Administration recommended an additional clinical trial in order to consider approval of voclosporin as a treatment for non-infectious uveitis, an eye inflammation. …
Lux Biosciences, which conducted the trials for treating uveitis, said it was ready to start an additional clinical study.
Read more about voclosporin’s potential as a new psoriasis treatment.
Category: Psoriasis Research, Treatment
Tags: cyclosporin, Isotechnika, uveitis, voclosporin
